Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages

Merus (NASDAQ:MRUS) has received a consensus rating of “Buy” from the fourteen analysts that are currently covering the firm, MarketBeat.com reports. Twelve research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $85.64.

MRUS has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $85.00 target price on shares of Merus in a research note on Monday, December 2nd. The Goldman Sachs Group initiated coverage on Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 target price for the company. UBS Group initiated coverage on Merus in a research note on Thursday, October 24th. They set a “buy” rating and a $72.00 target price for the company. Guggenheim reiterated a “buy” rating and set a $109.00 target price (down from $111.00) on shares of Merus in a research note on Tuesday, December 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $85.00 target price on shares of Merus in a research note on Monday, December 9th.

Hedge Funds Weigh In On Merus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gordian Capital Singapore Pte Ltd raised its holdings in Merus by 10.4% in the 3rd quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company’s stock valued at $250,000 after acquiring an additional 470 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Merus by 24.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 489 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in Merus by 2.2% in the 4th quarter. Harbor Capital Advisors Inc. now owns 43,208 shares of the biotechnology company’s stock valued at $1,817,000 after acquiring an additional 921 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Merus by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,517 shares of the biotechnology company’s stock valued at $610,000 after acquiring an additional 1,398 shares in the last quarter. Finally, nVerses Capital LLC raised its holdings in shares of Merus by 750.0% during the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after buying an additional 1,500 shares in the last quarter. 96.14% of the stock is owned by institutional investors and hedge funds.

Merus Stock Up 0.7 %

MRUS stock opened at $40.70 on Wednesday. The business has a 50 day moving average price of $42.70 and a two-hundred day moving average price of $48.47. The company has a market cap of $2.79 billion, a price-to-earnings ratio of -10.30 and a beta of 1.10. Merus has a twelve month low of $33.83 and a twelve month high of $61.61.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). The company had revenue of $11.77 million during the quarter, compared to the consensus estimate of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. On average, equities research analysts anticipate that Merus will post -3.89 EPS for the current fiscal year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.